论文部分内容阅读
目的 探讨全身静脉化疗加腹腔化疗双途径给药治疗卵巢上皮癌的疗效。方法 对 72例卵巢上皮癌患者均采用CAP方案化疗。A组 (38例 )环磷酰胺、阿霉素 (或吡喃阿霉素 )经静脉滴注 ,顺铂、干扰素经腹腔灌注 ;B组 (34例 )环磷酰胺、阿霉素 (或吡喃阿霉素 )及顺铂全部经静脉滴注。间隔 3～ 4周 ,共 6～ 8个疗程。结果 A组治疗总有效率 89.4 8% ,腹水得到有效控制 ;B组总有效率 6 7.6 5 %。两组比较有显著差异。两组 3年生存率分别为 4 7.37%、4 4 .12 % ,A组高于B组 ,但差异无统计学意义。结论 顺铂、干扰素腹腔灌注可减轻药物的副作用 ,提高治疗的总有效率 ,改善患者生存质量 ,但对提高 3年生存率的意义尚不肯定。
Objective To investigate the efficacy of systemic intravenous chemotherapy combined with intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Methods 72 cases of epithelial ovarian cancer patients were treated with CAP regimen. A group (38 cases) of cyclophosphamide, doxorubicin (or pirarubicin) by intravenous infusion of cisplatin, interferon by intraperitoneal perfusion; B group (34 cases) cyclophosphamide, doxorubicin (or Pirarubicin) and cisplatin all by intravenous drip. An interval of 3 to 4 weeks, a total of 6 to 8 courses. Results The total effective rate of group A was 89.4 8%, and ascites was effectively controlled. The total effective rate of group B was 6 7.6 5%. There were significant differences between the two groups. The 3-year survival rates of the two groups were 4 7.37% and 4 4 .12% respectively, but those in group A were higher than those in group B, but the difference was not statistically significant. Conclusions Cisplatin and interferon intraperitoneal perfusion can reduce the side effects of drugs, improve the total effective rate of treatment and improve the quality of life of patients, but the significance of improving 3-year survival rate is not yet confirmed.